Simulations Plus, Inc. · NASDAQ:SLP
Simulations Plus — Needham 23rd Annual Virtual Growth Conference (January 2021)
20 slides from Simulations Plus's conference presentation, Jan 15, 2021
Slide 1: Needham 23rd Annual Virtual Growth Conference
Needham 23 rd Annual Virtual Growth Conference January 14, 2021 (NASDAQ:SLP)
Slide 2: Safe Harbor Statement
With the exception of historical information, the matters discussed in this presentation are forward - looking statements that involve a number of risks and uncertainties . The actual results of the Company could differ significantly from those statements . Factors that could cause or contribute to
Slide 3: Company Overview
□ Industry - leading provider of modeling and simulation solutions used by major pharmaceutical, biotech, chemical, consumer goods companies and regulatory agencies worldwide □ Innovative software and services to improve drug development from discovery to regulatory approval with supportive guidance
Slide 4: Our Value Proposition
• Our solutions allow customers to model and predict results of chemical and biological tests required in the R&D process to improve success rates at multiple points in the process: − Computational AI models help scientists streamline and improve their processes − Machine learning improves the model
Slide 5: We Improve Drug Discovery and Development
We Improve Drug Discovery and Development Discovery Preclinical Development Clinical Studies Regulatory Approval MedChem Designer ADMET Predictor GastroPlus DDDPlus MembranePlus DILIsym Monolix NAFLDsym Consulting Services RENAsym 5
Slide 6: PKPD Software Solutions
PKPD Software Solutions Population PKPD Model to support dose regimen, risk exposure, clinical trial protocol design and analysis, drug label specifications and regulatory submission KIWI Monolix Suite Cloud - based data management application Datxplore PKanalix Mlxplore Monolix Simulx Exploration a
Slide 7: QSP/QST Software Solutions
QSP/QST Software Solutions Determine potential drug - induced liver injury hazard posed by individual drug candidates to support clinical trial optimization Additional QSP models NAFLDsym RENAsym DILIsym Assess the potential for drug - induced kidney injury of drug candidates to support clinical tri
Slide 8: PBPK Software Solutions and AI Data Mining
PBPK Software Solutions and AI Data Mining Simulating IV, oral, oral cavity, ocular, inhalation, skin and IM absorption, PBPK, PBBM, PD modeling and drug - drug interactions MembranePlu s MedChem Designer DDDPlus ADMET Predictor GastroPlus QSAR modeling enabling rapid prediction of 140+ ADMET proper
Slide 9: Services Solutions
• 70+ scientific PhD experts provide insightful solutions to improve the productivity of science - based drug development • Focusing on lead selection, pharmacology, ADMET and DMPK, dose regimen, efficacy and safety • Capabilities include: − Population PKPD data assembly, modeling, simulation, analy
Slide 10: Janssen Case Study: Accelerating Regulatory Interactions
Janssen Case Study: Accelerating Regulatory Interactions Virtual crossover trials to establish drug product specification after manufacturing changes • Janssen changed the manufacturing process to improve efficiencies with scale - up techniques post approval • FDA requested clinical study to confirm
Slide 11: In Silico Methods Improve the Probability of Phase Success
In Silico Methods Improve the Probability of Phase 3 Success Client Case Study: Strategic Use of Modeling & Simulation • Client with novel antibody for prophylactic use in competitive migraine market had Phase 3 development plan with predicted probability of success of <15% • Iteratively developed m
Slide 12: Revenue Growth Drivers
Revenue Growth Drivers Increasing acceptance of modeling and simulation by FDA and drug industry High customer satisfaction with ~95% software contract renewal rate (by fees) Recently improved and expanded sales infrastructure Increasing opportunities for product and service cross - selling Synergis
Slide 13: Consistent Year-over-Year Revenue Performance
$14.9 $17.0 $18.5 $21.6 $9.2 $12.7 $15.5 $20.0 FY17 FY18 FY19 FY20 Software Services Consistent Year - over - Year Revenue Performance 19% CAGR (in millions) 22% Growth 13 $ 24.1 $ 29.7 $ 34.0 $ 41.6
Slide 14: FY20 Software and Services Mix
FY20 Software and Services Mix 14 Software Products % of Total Revenues 34% 10% 4% 4% GastroPlus ADMET Predictor Monolix Suite* Other Software 10% 15% 23% PBPK QSP/ QST PKPD Services Offerings % of Total Revenues
Slide 15: Strategic Opportunities for Expansion and Growth
• Expand product offerings through opportunistic acquisitions − Fill gaps in the current product offerings − Focus on immediately or near - term accretive opportunities − Fragmented industry amenable to consolidation • Further expand global sales reach − Increase sales effort to drive new customer g
Slide 16: Q1 FY21 Performance & FY21 Full Year Outlook
• Total Revenue Growth − Q1 performance: 14% y/y growth − Full - year target range: 15 - 20% y/y organic growth plus 3 - 5% from Lixoft • Software Revenue Growth − Q1 performance: 35% y/y growth − Full - year target range: 20 - 25% y/y growth • Services Revenue Growth − Q1 performance: 6% y/y declin
Slide 17: Investment Highlights
• Provider of innovative modeling and simulation software and consulting services focused on pharmaceutical and biotechnology companies − Solutions from early discovery through regulatory approval • Pure play in the in silico drug discovery space • Growing acceptance of technology by regulators and
Slide 18: Financial Summary and Selected Financial Information
Financial Summary and Selected Financial Information Nasdaq SLP Q1 Cash and short - term investments $119M Q1 Borrowed Debt Outstanding $0 Market Capitalization (a/o 1/5/21) $1.5B Q1 Fully Diluted Shares Out 20.8M 30 - Day Average Daily Trading Volume (a/o 1/5/21) ~198K 18
Slide 19: Thank you!
19 Thank you! https://www.simulations - plus.com
Slide 20: References
1. J Health Econ . 2016 May;47:20 - 33. 2. Brochure: “Biopharmaceutical Research & Development: The Process Behind New Medicines” . PhRMA. 3. EvaluatePharma® World Preview 2017, Outlook to 2022, 10th Edition, June 2017, p. 19. References 20
Simulations Plus — Needham 23rd Annual Virtual Growth Conference (January 2021) on 6ix